TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02949206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
Study: NCT01670656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
Study: NCT01602926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgical technique - Chevron-type distal metatarsal osteotomy
Description: The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
Study: NCT02573935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VCD induction therapy
Description: Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
Study: NCT04639297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroVision® IONM
Description: Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
Study: NCT01602926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgical technique
Description: The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
Study: NCT04639297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Based IONM
Description: Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
Study: NCT02065713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
Study: NCT01602926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgical technique
Description: The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
Study: NCT02065713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
Study: NCT01669811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole (D961H) twice daily
Description: One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
Study: NCT03695705

Intervention type: DRUG
Group type: OTHER
Intervention: Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
Description: Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
Description: Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
Study: NCT01020799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: 15 mg, oral, twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 20 mg, oral, once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules to match AZD7268
Study: NCT01669811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole (D961H) once daily
Description: One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
Study: NCT03363412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTFE-covered stent grafts
Description: Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
Study: NCT00654784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: idebenone 450 mg/day (150 mg three times a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02877355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
Study: NCT01345344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease Education
Description: Providing information about fibromyalgia, including its potential causes and management approaches.
Study: NCT02701686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quit immediately (QI)
Description: advise to quit immediately using the AWARD model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cut down to quit (CDTQ)
Description: advise to reduce cigarette consumption and quit eventally using the AWARD model
Study: NCT01020799

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules to match AZD7268
Study: NCT02581111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone 8-mg IV bolus

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Study: NCT00568880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: bortezomib 1.0-1.3mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine 200 mg pill
Study: NCT01089582

Intervention type: OTHER
Intervention: No intervention
Study: NCT03719326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use
Study: NCT01020799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo tablets to match encapsulated escitalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets to match encapsulated escitalopram
Study: NCT04478461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W
Study: NCT03719326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549
Description: IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
Study: NCT04487405

Intervention type: DEVICE
Intervention: OVAnex
Description: OVAnex is a multivarite index assay assessing ovarian cancer risk

Intervention type: DEVICE
Intervention: OVAnex
Description: OVAnex is a multivarite index assay assessing ovarian cancer risk
Study: NCT03719326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549
Description: IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
Study: NCT02782091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Errands Test (MET)
Description: 1 hour assessment in an unknown district with 2 independent raters.
Study: NCT03719326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel (NP)
Description: NP is a microtubule inhibitor for intravenous (IV) use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel (NP)
Description: NP is a microtubule inhibitor for intravenous (IV) use
Study: NCT01690169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose of oral placebo administered.
Study: NCT00620971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
Study: NCT02949206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
Study: NCT03109119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
Study: NCT04063813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 40 minute up trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 40 minute down trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Two 20 minute up trials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Two 20 min down trials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Sedentary trial
Study: NCT04115163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT02972996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: 22 g freeze-dried whole blueberry powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 22 g placebo blueberry powder
Study: NCT02949206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
Study: NCT03109119

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
Study: NCT03447340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canteen and Behavior intervention
Description: canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canteen Only
Description: canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
Study: NCT00620971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
Study: NCT02349061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC
Description: Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant Medication
Description: Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant Medication
Description: Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
Study: NCT00620971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
Study: NCT04118114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL3-zumab
Description: IV administration every 2 weeks